Joe Reynolds Email and Phone Number
Joe Reynolds work email
- Valid
- Valid
- Valid
- Valid
Joe Reynolds personal email
- Valid
Joe Reynolds phone numbers
• Demonstrated pharmaceutical leader with experience across all stages of drug development (IND-enabling preclinical work through Phase 1, 2 and 3 studies through approval) spanning oncology, pulmonary disorders and rare diseases• Enterprise leader responsible for Program Management and Portfolio Strategy & Operations functions• Development program leader responsible for cross functional program teams• Advocated for, built, and led the Clinical Science department at Acceleron responsible for all Clinical Science activities across the Acceleron portfolio (including sotatercept for pulmonary arterial hypertension)• Experience with BLA and MAA filings leading to the approval of luspatercept-aamt (REBLOZYL®) for patients with myelodysplastic syndromes (MDS) and beta-thalassemia• Clinical leader responsible for the strategy, establishment, and execution of clinical development plans• Clinical trial experience spanning study start-up through study close out and CSR finalization• Demonstrated record of representing programs with internal and external stakeholders including collaborators (Celgene/Bristol Myers Squibb), senior/executive leadership, Board of Directors, regulatory authorities (FDA, EMA and PMDA), key opinion leaders, investigators, and patient groups
-
Executive Director, Global Clinical DevelopmentMerckWatertown, Ma, Us
-
Vice President, Portfolio Strategy And Development Program LeaderC4 Therapeutics, Inc. Sep 2023 - PresentWatertown, Ma, Us• Lead for the Program Management and Portfolio Strategy & Operations functions• Development Program Lead for CFT1946 (in development for the treatment of BRAF V600 mutant solid tumors including NSCLC, melanoma and colorectal cancer) and CFT8634 (previously in development for the treatment of SMARB1-perturbed cancers including synovial sarcoma) -
Vice President, Development Program LeadC4 Therapeutics, Inc. May 2022 - Sep 2023Watertown, Ma, Us• Development Program Lead for CFT8634 and CFT1946
-
Senior Director, Global Clinical Lead, Pulmonary FibrosisAcceleron Pharma Feb 2021 - Apr 2022Cambridge, Ma, Us• Global Clinical Lead of a cross functional team to establish and drive the Clinical Strategy and execution of Pulmonary Fibrosis Programs, including ACE-1334 a TGF-beta super-family ligand trap• Launch of the Phase 1b/2 trial in patients with Systemic Sclerosis (SSc)/SSc-associated interstitial lung disease (SSc-ILD)• Represent programs to leadership, internal and external stakeholders• Managed the Clinical Science function within Pulmonary Fibrosis to establish clinical and research collaborations to develop biomarker and translational science plans -
Senior Director, Clinical Lead Ace-1334Acceleron Pharma Jan 2020 - Apr 2022Cambridge, Ma, Us• Global Clinical Lead for the ACE-1334 program • Responsible for establishing the clinical strategy and the Clinical Development Plan for ACE-1334• Responsible the design of the first-in-patient Phase 1b study of ACE-1334 plus standard of care in participants with Systemic Sclerosis (SSc) and SSc-associated interstitial lung disease (SSc-ILD)• Recruited and managed external relationships including the program Steering Committee• Managed Clinical Scientists supporting ACE-1334
-
Senior Director, Head Of Clinical ScienceAcceleron Pharma Feb 2018 - Feb 2021Cambridge, Ma, Us• Head of Clinical Science at Acceleron Pharma managing a team of 5 Clinical Scientists providing support to the companies portfolio• In collaboration with Celgene/BMS, content author and team member for the submission of the BLA for REBLOZYL (luspatercept-aamt) leading to FDA approval for patients with MDS and beta-thalassemia• In collaboration with Celgene/BMS, content author and team member for the submission and approval of luspatercept-aamt for Marketing Authorisation by the EMA• Luspatercept subject matter expert supporting Commercial and Medical Affairs activities for the REBLOZYL launch• Subject matter expert for luspatercept Clinical Development in response to Health Authority questions• Clinical Scientist supporting the Clinical Development of luspatercept including the Phase 2 and Phase 3 studies (in collaboration with Celgene/BMS) across multiple indications
-
Director, Clinical ScienceAcceleron Pharma Jan 2017 - Jan 2018Cambridge, Ma, UsDirector of Clinical Science focusing on:• The development of luspatercept for myelodysplastic syndromes (MDS) and beta-thalassemia• The development of sotatercept for pulmonary arterial hypertension (PAH)
-
Associate Director, Clinical Science And Drug DevelopmentMerrimack Dec 2014 - Jan 2017Cambridge, Massachusetts, UsAssociate Director of Clinical Science and Drug Development for MM-302 focusing on:• Medical monitoring of ongoing studies• Ensuring maintenance of clinical study conduct• Overseeing all program-specific clinical science activities• Relationship building with clinical investigators and key opinion leaders (KOLs)• Global long-term drug development strategy • Representing the program in face-to-face global regulatory interactions (FDA, European Medicines Agency (EMA), Japanese Pharmaceutical and Medical Devices Agency (PMDA))• Authoring various clinical documents (clinical protocols, regulatory briefing documents, investigator brochures, etc.)• Cross functional liaison (medical, clinical, regulatory, CMC, research, data management/statistics)• Developing and managing the external communication strategy for MM-302• Liaison to patient advocacy community for all Merrimack breast cancer drug candidates -
Principal Clinical ScientistMerrimack Dec 2013 - Dec 2014Cambridge, Massachusetts, UsPrincipal Clinical Scientist for MM-302 focusing on:• Medical monitoring• Development of study safety documents• Development of the strategy for investigator and KOL identification and study recruitment• Preparation of a briefing documents for regulatory interactions• Representing the program at regulatory interactions• Presentation and design of material and key messages for various internal and external stakeholders• Cross functional liaison• Translational research
-
Senior Clinical ScientistMerrimack Nov 2012 - Dec 2013Cambridge, Massachusetts, UsSenior Clinical Scientist for MM-302 (a HER2-targeted PEGylated liposomal doxorubicin) focusing on:• Clinical development• Oncology clinical trial design, feasibility and implementation• Synopsis and clinical protocol writing• Analysis and interpretation of clinical data• Ensuring maintenance of clinical study conduct• Patient safety monitoring• Doxorubicin-mediated cardiotoxicity• Translational research• Scientific and clinical knowledge of disease landscapes • Standard of care treatments in oncology• Assessing ongoing clinical trials and forecasting how their outcome impacts the treatment landscape
-
Senior ScientistMerrimack Jan 2011 - Nov 2012Cambridge, Massachusetts, UsSenior Scientist for MM-302 (a HER2-targeted PEGylated liposomal doxorubicin) focusing on:• Drug discovery• Early stage clinical development• Stem cell-derived cardiac models and their use as a preclinical toxicity screening platform• High content microscopy (HCM) and quantitative analysis• Deconvolution microscopy • In vitro mechanism of action studies• Cell proliferation and cytotoxicity assays
-
ScientistMerrimack Jul 2008 - Jan 2011Cambridge, Massachusetts, UsScientist for an early stage drug discovery project and MM-302 (a HER2-targeted PEGylated liposomal doxorubicin) focusing on:• Early stage preclinical drug discovery• Therapeutic target identification and validation• IND enabling studies • Drug mechanism of action • Microscopy• Quantitative protein, cell viability and cytotoxicity assays
-
Call/Volunteer Fire FighterBoxford Fire Department Jun 2012 - Jul 2014
Joe Reynolds Skills
Joe Reynolds Education Details
-
Boston UniversityCell Biology And Biochemistry -
Boston University& Biochemistry
-
Bates CollegeBiochemistry
-
Winnacunnet High School
Frequently Asked Questions about Joe Reynolds
What company does Joe Reynolds work for?
Joe Reynolds works for Merck
What is Joe Reynolds's role at the current company?
Joe Reynolds's current role is Executive Director, Global Clinical Development.
What is Joe Reynolds's email address?
Joe Reynolds's email address is jr****@****rma.com
What is Joe Reynolds's direct phone number?
Joe Reynolds's direct phone number is +161757*****
What schools did Joe Reynolds attend?
Joe Reynolds attended Boston University, Boston University, Bates College, Winnacunnet High School.
What skills is Joe Reynolds known for?
Joe Reynolds has skills like Drug Discovery, Clinical Development, Assay Development, Oncology, Drug Development, Cell Culture, Elisa, Molecular Biology, Translational Research, In Vitro, Western Blotting, Biopharmaceuticals.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial